eCommons@AKU
Department of Pathology and Laboratory Medicine

Medical College, Pakistan

January 2007

Comparative predictive value of three prognostic
markers--S-phase fraction, PCNA and mitotic
count on axillary lymph node metastasis in
carcinoma breast
Shahid Pervez
Aga Khan University

Muhammad Nadeem Khan
Aga Khan University

Muhammad Israr Nasir
Aga Khan University

Follow this and additional works at: http://ecommons.aku.edu/
pakistan_fhs_mc_pathol_microbiol
Part of the Microbiology Commons, Obstetrics and Gynecology Commons, Oncology
Commons, Pathology Commons, and the Women's Health Commons
Recommended Citation
Pervez, S., Khan, M. N., & Nasir, M. I. (2007). Comparative predictive value of three prognostic markers--S-phase fraction, PCNA and
mitotic count on axillary lymph node metastasis in carcinoma breast. Journal of Ayub Medical College,19(1), 3-5.

J Ayub Med Coll Abbottabad 2007; 19(1)

COMPARATIVE PREDICTIVE VALUE OF THREE PROGNOSTIC
MARKERS S-PHASE FRACTION, PCNA AND MITOTIC COUNT ON
AXILLARY LYMPH NODE METASTASIS IN CARCINOMA BREAST
Shahid Pervez, Muhammad Nadeem Khan, Muhammad Israr Nasir
Section of Histopathology, Department of Pathology & Microbiology, The Aga Khan University P.O. Box 3500, Stadium Road Karachi

Background: Axillary lymph node metastasis is the single most important prognostic factor in
carcinoma of the breast. Therefore , prognostic markers that may reliably predict probability of
lymph node (LN) metastases are of great value. This study was conducted to compare the
predictive value of two novel prognostic / proliferative markers i.e. S-phase fraction (SPF) and
proliferating cell nuclear antigen (PCNA) in parallel with mitotic index. Methods: Data of
consecutive cases of infiltrating ductal carcinoma (IDC) breast diagnosed from July 2003 to July
2004 at the section of the Histopathology, The Aga Khan University Hospital, Karachi, were
reviewed. A total of 112 cases of infiltrating ductal carcinoma (IDC) of the breast with axillary LN
sampling were selected. SPF was calculated by flow cytometry while PCNA staining was done by
immunohistochemistry. Mitotic count was calculated according to modified Bloom and
Richardson’s grading guidelines. Result: It was observed that the number of axillary LN
metastases was increased with higher SPF (p value: 0.008). However no significant difference
was found between the results of various categories of PCNA on axillary LN metastases
(p value: 0.182) and mitotic count with axillary lymph node metastases (p value: 0.324).
Conclusion: It was concluded that mitotic count and / PCNA alone cannot be used in predicting
axillary LN metastases. SPF was found to be a more reliable marker compared to PCNA reactivity
and conventional mitotic count in predicting axillary LN metastases.
Keyword: S-phase fraction, Proliferating cell nuclear antigen, Mitosis, Axillary Lymph node.

INTRODUCTION
Breast Cancer is the most common malignancy in
women in Pakistan. It constitutes approximately 33.4%
of all cancers in women in Karachi1 . There are several
conventional prognostic markers, which predict the
overall survival (OS) in breast cancer patients. These
include tumor size, tumor grade and axillary LN status
etc. Axillary LN status is considered to be the single
most important predictor of OS in breast cancer
patients 2-4 . With the passage of time and advancement
in medical technology a number of novel prognostic
markers have emerged. These include DNA ploidy5 , sphase fraction (SPF)5,6 , proliferative markers like
Proliferating Cell Nuclear Antigen (PCNA)7 , p-53, CErb-B2/Her2, Cathepsin D, Epidermal Growth Factor
Receptor (EGFR) etc. According to various studies
some of these markers are relatively reliable while
others appear to be of no significance and thus some of
these markers in different studies contradict each
other’s results 5,6,8,9 . SPF represents the proportion of
cells preparing for mitosis by their active replication of
DNA content in the S-phase of cell cycle 8 . PCNA
(Cyclin) is an auxiliary protein of DNA polymerase
and the level of its synthesis correlates directly with
rates of cellular proliferation and DNA synthesis. This
protein is associated with cell cycle & accumulates in
the nuclei of proliferating cell in the late G1 and Sphase 10 . Mitotic index is defined as the number of
mitotic figures in any given area of tumor3 . In this

study it was evaluated that among three prognostic
markers, mitotic count (conventional), PCNA (novel)
& SPF (novel), we can utilize mitotic count and or
PCNA alone as an alternate low cost test to predict
axillary LN metastasis in our breast cancer patients.

MATERIAL AND METHODS
The study was conducted in the section of the
Histopathology at Aga khan university hospital,
Karachi. Only those cases were included in the study
in which besides the main tumour, axillary lymph node
sampling was also done. For mitotic count, modified
Bloom and Richardson criteria was used. A score of I
was given to less than 10 mitoses/10hpf, II for 11-19
mitoses/10 hpf and III for ≥ 20 mitoses/10hpf.
For PCNA estimation immunohistochemistry
was employed using PAP method. Anti mouse PCNA
monoclonal antibody (Clone PC 10), a mouse IgG
antibody (Dako) was used at a dilution of 1/25.
Immunostaining was performed on 4µm thick section
on Poly-L-Lysine coated slides. Diamino-benzidine
(DAB) was employed as a chromogen. Positive
staining for PCNA was seen in the nuclei. PCNA
positivity was divided into two categories. Positivity
of 25% nuclei or less was considered as low while
greater than 25% was regarded as high.
For estimation of SPF, flow cytometric
technique was employed using 25 µm thick formalin
fixed paraffin embedded tissue sections. Sections were
dewaxed in two changes (2 X 10 minutes) of xylene
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and rehydrated in 100%, 90%, 70% & 50% of alcohol
for 10 minutes each. The sections were then rinsed in
PBS X 10 minutes and incubated in 0.5% Pepsin
solution at pH 1.5 at 37°C for 30 minutes. Hypodermic
needles of 40 & 25 bore were then used to break up the
tissue. Released nuclei were then spun, washed and
cytopreps made to check their condition. These were
then stained with Propidium Iodide in isoton
(250µg/ml) containing 1mg/ml RNAase for 30 minutes
at 4°C before analysis on FAC Scan (B&D) flow
cytometer using the software MODFIT version 1.01
for data acquisition and analysis. Flow cytometric data
was acquired and displayed in two standard parameter
dot plots using FL2 width and FL2 areas as the axis.
This allowed us to draw gates in which debris below
the first G0/G1 distribution and particles with extended
time in flight (presumed dublets) were excluded from
analysis using carefully defined and standardized
gating criteria. FL2 area signals were then used to
generate single parameter DNA histograms. A total of
10,000 nuclei were counted in each case. Specimens
were rejected if the median half peak coefficient of
variation (CV) of the diploid peak was more than 5.
Peak channels of diploid, aneuploid and G2M were
estimated along with fitting a rectangle between two
peaks to calculate SPF by MODFIT model. SPF values
were divided into two categories i.e. equal to or less
than 10 % was considered as low and greater than 10%
as high. Axillary LN status was divided into three
categories i.e. Negative lymph nodes (I), one to three
lymph nodes positive (II), and four or more lymph
nodes positive (III).
The statistical analysis of the data was
performed using SPSS 13 software. Students‘t’ test
and chi square test were employed.

number of axillary LN metastases was higher with
higher SPF (p value=0.008).
Table 1- Relationship of mitosis versus axillary lymph
node metastasis
Metastatic LN (Number)
Total
Mitosis
0
(1-3)
(4 and above)
I
8
8
8
24
II
27
12
24
63
III
8
10
7
25
Total
43
30
39
112

p value = 0.324
Table 2 - Relationship of PCNA versus axillary lymph
node metastasis
Metastatic LN (Number)
Total
PCNA
0
(1-3)
(4 or more)
23
13
13
49
≤ 25
> 25
20
17
26
63
Total
43
30
39
112
p value = 0.182
Table 3 - Relationship of S PF versus axillary lymph node
metastasis
Metastatic LN (Number)
SPF
(1-3)
(4 or more)
Total
2
1
13
≤10
>10
28
38
99
Total
30
39
112
p value = 0.008

RESULTS
A total of 112 cases of IDC of breast were included in
the study. 24 cases had mitotic score I (less than 10
mitoses/10hpf), 63 cases had mitotic score II (10-19
mitoses/10hpf) and 25 cases had mitotic score III
(≥20mitoses/10hpf). It was found that relationship
between mitotic count and axillary LN metastasis was
not significant (p value: 0.324). PCNA positivity was
seen in every case (Fig 1), ranging from 5% to 60%
(mean 28.25%). In 49 cases , PCNA value was found to
be equal to or less than 25%, while in the remaining 63
cases it was greater than 25%. No significant
correlation was observed between PCNA and axillary
LN metastasis (p value: 0.182). S-phase fraction
ranged from 3.26% to 54.3% (mean 22.83%). As for as
axillary LN status is concern ed, 43 cases had no lymph
nodes (I), 30 cases had one to three lymph nodes
positivity (II), whereas 39 cases had four or more
lymph nodes positivity (III). It was observed that the
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Figure 1 - Photomicrograph of infiltrating ductal
carcinoma of breast stained with a monoclonal antibody
against PCNA (PC10). Note brown nuclear staining in a
large number of tumour cells (Arrow)

DISCUSSION
This study did not reveal any significant correlation
between axillary LN metastases and mitotic count,
whereas in contrast many other studies did notice
significant correlation.4,5,11 It may be due to a number
of factors like variation in selection of the mitotically
active areas, personal bias on accepting a mitotic
figure, lack of standardization of the size of hpf etc.
The authorities recommend that mitotic counts should
be calculated at ten consecutive most mitotically active
hpf of the tumour. Secondly to avoid personal bias,
only clearly identifiable mitotic figures should be
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counted (like cells in prophase, metaphase and
anaphase). Similarly size of the hpf should be
standardized according to modified Bloom and
Richardson grading criteria 3 .
PCNA
is
done
by
a
simple
immunohistochemical technique. In this study 1000
cell nuclei were counted and then percentage of
positively stained nuclei was calculated. It is a simple,
cost effective and non-radioactive technique. However,
uptill now role of PCNA as a reliable prognostic
marker is not well established. Lack of association
between PCNA and axillary lymph node status in our
study is in agreement with most previous studies7,12,13 .
In studying PCNA mostly PC 10 antibodies were used
which is substantially affected by fixation. Recently a
new antibody (19a2) has emerged which is not
affected much by the duration of fixation. Furthermore
PCNA may be expressed in response to injury even in
non-proliferating cells 14 . These factors together with
the findings of our study suggest that PCNA is not a
consistently useful marker of proliferation nor is it a
good predictor of axillary LN metastases in breast
cancer patients.
This study, however, identified a significant
correlation between SPF and axillary lymph node
metastases. In our study SPF ranged from 3.26% to
54.30% with a mean of 22.83%. Our mean value was
found to be higher than those reported by some other
studies3,15,16 . This difference in SPF could be due to
variation in the interpretation of DNA histogram and
differences of methodology of flowcytometric
techniques, staining and sample preparation in various
centers17 . It is also suggested that the patients in
Pakistan have a different and more aggressive disease,
thus more cells are in the synthetic phase of the cell
cycle 8 . In our patients mean tumor size was 5.04 cm
with a standerd deviation of ± 3.35.
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CONCLUSION
It was concluded that mitotic count and PCNA alone
cannot be used to predict axillary LN metastases in
breast cancer patients. SPF was found to be more
reliable marker compared to PCNA reactivity and
conventional mitotic count in predicting axillary LN
metastases. This could be due to subjective
interpretation of the latter two markers compared to
better standardized SPF estimation.
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